Here are three details to know:
1. Expanding cells in hypoxic culture conditions affects cell fitness and gene expression that may contribute to cell potency and therapeutic benefits.
2. Hypoxia may be of importance in selection and conditioning cells to be best suited for the specific microenvironment of the disc in order to obtain optimal therapeutic response.
3. The study showed that hypoxic culturing improves mesenchymal stem cell properties and positively influences whole genome expression profiles when referencing the development of cellular therapies targeting the microenvironment of the intervertebral disc.
The product is currently in an FDA-authorized phase two clinical trial, and it will potentially be used as an outpatient treatment in the future.
More articles on outpatient spine:
Arete Surgical Center completes 1st case with Mazor Robotics’ system — 4 things to know
Why Dr. Robert Masson aims to participate in BPCI Advanced bundled payments for spine
CMS reviewing same-day spine cases for beneficiaries — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.